Personalis, Inc.
PSNL
Positions held
Your positionsPSNL isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Personalis, Inc. operates in the rapidly growing diagnostics and research sector, which is crucial for personalized medicine and has significant market potential.
- Revenue increased by 44% compared to the prior quarter, reaching $22 million.
- Gross margin improved to 21.2%, up from 1.8% in the previous quarter.
- The company has a high debt-to-equity ratio of 16.157, indicating potential financial risk.
- Operating margin remains negative at -150.2% for the latest quarter.
- Net income for 2026-Q2 was -31.683 million, reflecting ongoing losses.
Fundamentals
| Market cap | $1.72B | Enterprise value | $1.54B | Trailing P/E | — | Forward P/E | -17.09 |
| PEG | — | Price / book | 7.26 | Beta | 2.32 | Dividend yield | 0.00% |
| Revenue growth | 30.0% | Earnings growth | — | Gross margin | 12.7% | Operating margin | -1.5% |
| Profit margin | -1.5% | ROE | -50.3% | ROA | -25.0% | Debt / equity | 0.16 |
| Current ratio | 5.28 | Free cash flow | -$56.03M | Analyst recommendation | hold | Mean target | $15.17 |
| 52w high | $18.89 | 52w low | $4.96 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $22.4M | $15.5M | $17.3M | $14.5M | $17.2M |
| Op margin | -150.2% | -207.9% | -145.7% | -160.7% | -126.7% |
| Net income | -$31.7M | -$30.0M | -$23.8M | -$21.7M | -$20.1M |
| Gross margin | 21.2% | 1.8% | 11.0% | 13.2% | 27.6% |
| Gross profit | $4.7M | $0.3M | $1.9M | $1.9M | $4.8M |
| Operating income | -$33.6M | -$32.2M | -$25.3M | -$23.3M | -$21.8M |
- Revenue +44% vs prior quarter ($22M vs $15M).
- Gross margin 21.2% (was 1.8% prior quarter).
- Operating margin expanded to -150.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $69.6M | $84.6M | $73.5M | $65.0M | — |
| Op margin | -126.4% | -80.7% | -131.0% | -177.6% | — |
| Net income | -$81.3M | -$81.3M | -$108M | -$113M | — |
| Gross margin | 22.7% | 31.7% | 24.8% | 20.5% | — |
| Gross profit | $15.8M | $26.8M | $18.2M | $13.3M | — |
| Operating income | -$88.1M | -$68.3M | -$96.3M | -$116M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · BTIG Downgrades Personalis to Neutral From Buy
2026-09-22 · Tempus AI Sees Pricing, Data Growth Fueling Long-Term Expansion
2026-09-17 · Tempus AI Stock Surges as Revenue Optimism Boosts Winning Streak
2026-09-04 · The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels.
2026-09-01 · Piper Sandler Lifts Tempus AI to Overweight at $76
2026-09-01 · Tempus AI shares rise 2.7% following analyst actions
2026-08-27 · Tempus AI (TEM) Jumped on Moderna’s Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated?
2026-08-26 · Personalis Stock Is Up 250% in the Past Year. It Needs to Turn a Profit Next.
2026-08-24 · Sector Update: Healthcare Stocks Softer Late Afternoon
2026-08-24 · Sector Update: Healthcare
2026-08-24 · Personalis Shares Fall After Craig-Hallum Downgrade
2026-08-24 · Craig-Hallum Downgrades Personalis to Hold From Buy, Price Target is $16.25
Price (daily)
Full chart · RSI · MACD · patterns